Skip to Content

CME Group Inc Class A

CME: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$196.00MkkDdxctjnxr

CME Stands to Benefit From Rising Interest Rates as Volatility Returns to Its Markets

Business Strategy and Outlook

CME has suffered from little to no revenue growth more recently as all its futures complexes reported lower trading volume in 2021 than in 2019, with the notable exception being its equity futures platform, which remains well above prepandemic levels. The most significant headwind for the company has been the impact that low short-term interest rates has had on its interest rate complex, which is its largest source of revenue. When interest rates are expected to stay low there is less need for interest rate hedging and less incentive for speculation, creating a drag on CME's trading volume. With interest rates now rising, though, this drag has been removed and the company's results have improved so far in 2022. After a couple years of meager revenue growth, we see CME enjoying more favorable market conditions in the near term.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CME so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center